Literature DB >> 9987477

Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century.

G J Annas1, S Elias.   

Abstract

The Titanic has become a metaphor for the disastrous consequences of an unqualified belief in the safety and invincibility of new technology. Similarly, the thalidomide tragedy stands for all of the "monsters" that can be inadvertently or negligently created by modern medicine. Thalidomide, once banned, has returned to the center of controversy with the Food and Drug Administration's (FDA's) announcement that thalidomide will be placed on the market for the treatment of erythema nodosum leprosum, a severe dermatological complication of Hansen's disease. Although this indication is very restricted, thalidomide will be available for off-label uses once it is on the market. New laws regarding abortion and a new technology, ultrasound, make reasonable the approval of thalidomide for patients who suffer from serious conditions it can alleviate. In addition, the FDA and the manufacturer have proposed the most stringent postmarketing monitoring ever used for a prescription drug, including counseling, contraception, and ultrasonography in the event of pregnancy. The Titanic/thalidomide lesson for the FDA and public health is that rules and guidelines alone are not sufficient to guarantee safety. Continuous vigilance will be required to ensure that all reasonable postmarketing monitoring steps are actually taken to avoid predictable and preventable teratogenic disasters.

Entities:  

Keywords:  Celgene; Genetics and Reproduction; Legal Approach; Professional Patient Relationship; Twentieth Century

Mesh:

Substances:

Year:  1999        PMID: 9987477      PMCID: PMC1508516          DOI: 10.2105/ajph.89.1.98

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  10 in total

1.  Recognition of thalidomide defects.

Authors:  R W Smithells; C G Newman
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

2.  Fetal protection and employment discrimination--the Johnson Controls case.

Authors:  G J Annas
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

3.  Thalidomide: was the tragedy preventable?

Authors:  A Dally
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

4.  Time to act on drug safety.

Authors:  T J Moore; B M Psaty; C D Furberg
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 5.  Drugs in pregnancy.

Authors:  G Koren; A Pastuszak; S Ito
Journal:  N Engl J Med       Date:  1998-04-16       Impact factor: 91.245

Review 6.  The thalidomide syndrome: risks of exposure and spectrum of malformations.

Authors:  C G Newman
Journal:  Clin Perinatol       Date:  1986-09       Impact factor: 3.430

7.  The broader message of accutane.

Authors:  S R Shulman
Journal:  Am J Public Health       Date:  1989-11       Impact factor: 9.308

8.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  J M Jacobson; J S Greenspan; J Spritzler; N Ketter; J L Fahey; J B Jackson; L Fox; M Chernoff; A W Wu; L A MacPhail; G J Vasquez; D A Wohl
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

9.  Formed by thalidomide: mass torts as a false cure for toxic exposure.

Authors:  A Bernstein
Journal:  Columbia Law Rev       Date:  1997-11

10.  Thalidomide, a current teratogen in South America.

Authors:  E E Castilla; P Ashton-Prolla; E Barreda-Mejia; D Brunoni; D P Cavalcanti; J Correa-Neto; J L Delgadillo; M G Dutra; T Felix; A Giraldo; N Juarez; J S Lopez-Camelo; J Nazer; I M Orioli; J E Paz; M A Pessoto; J M Pina-Neto; R Quadrelli; M Rittler; S Rueda; M Saltos; O Sánchez; L Schüler
Journal:  Teratology       Date:  1996-12
  10 in total
  12 in total

1.  A new opportunity for thalidomide? Further randomised controlled trial are necessary.

Authors:  Federico Marchetti; Marzia Lazzerini; Alessandro Ventura
Journal:  Eur J Clin Pharmacol       Date:  2004-09-03       Impact factor: 2.953

2.  Birth defects surveillance in China.

Authors:  Li Dai; Jun Zhu; Juan Liang; Yan-Ping Wang; He Wang; Meng Mao
Journal:  World J Pediatr       Date:  2011-10-20       Impact factor: 2.764

3.  American medicine as religious practice: care of the sick as a sacred obligation and the unholy descent into secularization.

Authors:  Margaret P Wardlaw
Journal:  J Relig Health       Date:  2011-03

4.  Chiral xenobiotics bioaccumulations and environmental health prospectives.

Authors:  Iqbal Hussain; Zeid A ALOthman; Abdulrahman A Alwarthan; Mohd Marsin Sanagi; Imran Ali
Journal:  Environ Monit Assess       Date:  2015-07-07       Impact factor: 2.513

5.  Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?

Authors:  Marc Maliepaard; Anne C Taams; Cynthia Sung; Jalene Poh; Yang Yu
Journal:  Pharmaceut Med       Date:  2019-10

6.  Mental Disorders in People Affected by Thalidomide.

Authors:  Alexander Niecke; Klaus Peters; Christina Samel; Kristin Forster; Markus Lüngen; Holger Pfaff; Christian Albus
Journal:  Dtsch Arztebl Int       Date:  2017-03-10       Impact factor: 5.594

7.  Placental transfer of ondansetron during early human pregnancy.

Authors:  Shing-Shun N Siu; Matthew T V Chan; Tze-Kin Lau
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  The survey of birth defects rate based on birth registration system.

Authors:  Min Yu; Zhiguang Ping; Shuiping Zhang; Yuying He; Rui Dong; Xiong Guo
Journal:  Chin Med J (Engl)       Date:  2015-01-05       Impact factor: 2.628

9.  Epidemiology of Birth Defects Based on a Birth Defect Surveillance System from 2005 to 2014 in Hunan Province, China.

Authors:  Donghua Xie; Tubao Yang; Zhiyu Liu; Hua Wang
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

10.  Epidemiology of birth defects based on surveillance data from 2011-2015 in Guangxi, China: comparison across five major ethnic groups.

Authors:  Jichang Chen; Xuemei Huang; Bo Wang; Yu Zhang; Chokechai Rongkavilit; Dingyuan Zeng; Yongjiang Jiang; Ba Wei; Chawla Sanjay; Eric McGrath
Journal:  BMC Public Health       Date:  2018-08-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.